Objectives: To estimate UK prevalence and incidence of clinically significant carbapenemase-producing Enterobacteriaceae (CPE), and to determine epidemiological characteristics, laboratory methods and infection prevention and control (IPC) measures in acute care facilities.
Introduction
In the UK, carbapenem-non-susceptible Enterobacteriaceae were rarely observed before the mid-2000s. 1 2 and by 31% from 2010 to 2013, 3 increasing selection pressure on Enterobacteriaceae. There is no mandatory surveillance or reporting of carbapenemase-producing Enterobacteriaceae (CPE) in the UK, although clinical laboratories are encouraged to submit suspect isolates to AMRHAI, so the prevalence and incidence of CPE are unclear. 4 Nevertheless, the number of CPE sent to AMRHAI has increased yearly since 2008 (N. Woodford, AMRHAI, unpublished results). A few UK CPE outbreaks have been described, notably of KPC producers in northwest England 4 and OXA-48 producers in a London renal unit. 5 CPE and their resistance plasmids have the capacity to spread rapidly and cause outbreaks in healthcare facilities. In addition, since E. coli (and to a lesser extent K. pneumoniae) frequently cause community-acquired infections, there is potential for spread in the community. This would considerably complicate treatment, as oral options for antibiotic therapy are severely limited for most CPE. 6 The economic burden of CPE is also substantial. 7 Moreover, carbapenem-non-susceptible Enterobacteriaceae are associated with higher mortality than susceptible isolates. 8, 9 In 2010, the ECDC brought together national experts from 31 European countries to elaborate a strategy to fight carbapenemnon-susceptible Enterobacteriaceae. 10 The European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) project was thus developed, with a focus on E. coli and K. pneumoniae, the two Enterobacteriaceae most frequently isolated in the ECDC point prevalence survey on healthcare-associated infections in 2011-12. 11 The ultimate objective of the EuSCAPE project was to estimate the prevalence and incidence of clinically significant carbapenem-non-susceptible Enterobacteriaceae and CPE in each participating country, their antibiotic susceptibilities, resistance mechanisms and epidemiological characteristics; these composite data, from sentinel surveys in each country, will be presented elsewhere. Here, we report the results for 'EuSCAPE-UK', which sought also to determine the laboratory methods used to detect CPE in the recruited sentinel laboratories and the infection prevention and control (IPC) measures in place in the associated acute care hospitals.
Methods
AMRHAI and Health Protection Scotland recruited 22 sentinel hospital laboratories from all UK regions. However, the data for two Scottish Microbiology Reference Laboratories were subsequently supplied 'pooled' and these had to be considered as a single entity and analysed collectively (n ¼21). The number of laboratories per region was determined according to the geographical distribution of the population. Major laboratories from the different regions were contacted to build the sample. The number of recruited sites was decided by the ECDC according to the country population size for uniformity of the European isolates collection. The inclusion criterion for laboratories was routine testing of all clinical isolates of Enterobacteriaceae against ≥1 carbapenem.
Isolate collection
The EuSCAPE survey ran for 6 months, from November 2013 to April 2014. Participants were asked to collect up to 10 consecutive, non-replicate, non-susceptible to any carbapenem (ertapenem, meropenem or ertapenem) and clinically significant isolates (no surveillance or screening samples) of E. coli or K. pneumoniae, as determined by local susceptibility testing.
The following non-nominative information was collected for each isolate and patient: sample type, gender, age, previous hospital admission and travel abroad in the last 6 months, ward and source of referral (community, inpatient for ≤48 h or inpatient .48 h). The participants also recorded the total number of non-replicate, clinically significant E. coli or K. pneumoniae that were isolated either during the period necessary to collect the 10 carbapenem-non-susceptible E. coli or K. pneumoniae or during the entire 6 month survey period if ,10 carbapenem-nonsusceptible isolates were detected.
Laboratory identification and susceptibility testing
Both AMRHAI and the Scottish Microbiology Reference Laboratories were required to participate successfully in a proficiency test organized and analysed by the UK National External Quality Assessment Service (UK NEQAS) before participating in the survey. This proficiency test was designed specifically for the EuSCAPE project and assessed the accuracy of both phenotypic susceptibility testing and molecular detection of carbapenemases.
Bacterial identification was confirmed by AMRHAI using MALDI-TOF MS (Bruker, Bremen, Germany). Antibiotic susceptibility was performed by agar dilution against AMRHAI's standard Gram-negative antibiotic panel using BSAC methods and breakpoints. 12 Isolates confirmed to be nonsusceptible to ≥1 carbapenem were tested by in-house PCR for carbapenemases including KPC, NDM, OXA-48-like, VIM and IMP. 13 -16 For the Scottish isolates, identification and susceptibility testing was confirmed by VITEK w 2 (bioMérieux, Marcy-l ′ Étoile, France), Etest w (bioMérieux) and BSAC methods and breakpoints. 12 Isolates non-susceptible to ≥1 carbapenem were tested by in-house PCR for KPC, NDM, OXA-48-like and VIM carbapenemase genes at the Scottish Microbiology Reference Laboratories. OXA-48-like and VIM genes were screened for using AMRHAI's PCRs, whilst KPC and NDM genes were screened for using primers recommended by the EuSCAPE protocol. A Rapid CARB Screen Kit (Rosco Diagnostica, Taastrup, Denmark) and carbapenemase detection set D70C (Mast Group, Bootle, UK) were also used.
K. pneumoniae and E. coli isolates found positive for a carbapenemase are subsequently referred to here as CPE.
Questionnaire on laboratory methods and IPC measures for CPE
Clinical microbiologists from each participating laboratory were invited to complete a questionnaire (available as Supplementary data at JAC Online) designed to investigate: (i) carbapenemase detection during the year before the EuSCAPE survey; (ii) laboratory detection methods used; (iii) IPC measures in place against CPE; and (iv) awareness of the existing guidelines in the UK for laboratory detection of CPE and IPC measures to prevent onwards transmission.
Data analysis
Period prevalence of carbapenem-non-susceptible E. coli and K. pneumoniae was calculated. The numerator was the number of carbapenem-nonsusceptible E. coli and K. pneumoniae isolated during the study period (or until the laboratory collected 10 isolates, whichever was shorter), including only the first isolate per patient. The denominator was all clinical isolates of E. coli and K. pneumoniae collected during the study period (or until the Epidemiology of CPE in the UK JAC laboratory collected 10 isolates, whichever was shorter), including only the first isolate per patient. The prevalence of carbapenemase-producing E. coli and K. pneumoniae was calculated with the same denominator.
An isolate was considered hospital acquired (versus community onset) if the patient was hospitalized for .48 h when it was collected. Incidence per 1000 patient-days was estimated using the number of beds and average percentage of bed occupancy during the study period (or the number of days until the laboratory collected 10 isolates, whichever was shorter). Exact 95% CIs were calculated considering a binomial distribution for proportions and a Poisson distribution for rates. The exact Fisher's test was used to compare proportions. Statistical analyses were performed with STATA 13.1 Special Edition.
Results
The 21 sentinel sites were in all UK regions and represented around 11% of UK clinical microbiology laboratories (based on 199 laboratories participating in the UK NEQAS). The number of laboratories per region was based on the population distribution. The laboratories were all part of an acute care hospital and served tertiary, secondary and primary care centres. The median number of beds per laboratory was 1000 (IQR¼ 738 -1818).
Clinical isolates
During the period until each laboratory had collected 10 isolates, or the full 6 months, whichever was shorter, 104295 clinical isolates of E. coli or K. pneumoniae were collected by 19 laboratories (data not available for 2 laboratories) from single successive patients (mean per laboratory ¼ 5489; standard deviation ¼ 3830). These included 98444 E. coli (mean¼5181, standard deviation¼3631) and 5851 K. pneumoniae (mean¼308, standard deviation¼337).
During the study period, 102 isolates suspected to be nonsusceptible to ≥1 carbapenem (47 E. coli and 55 K. pneumoniae) were submitted by 17 participating laboratories (81%). Three of the four remaining laboratories confirmed that they did not identify any isolate meeting the study criterion during the survey period. All UK regions except the east of England detected ≥1 suspected carbapenem-non-susceptible isolate that met the inclusion criterion during the 6 month survey period. However, one region failed to submit its isolates for reference investigation within the permitted period. Only four laboratories, in Yorkshire and the Humber, and Scotland, submitted the maximum 10 suspected carbapenem-non-susceptible isolates.
Mechanisms of carbapenem resistance
The reference laboratories confirmed that 89/102 isolates (87%) were non-susceptible to ≥1 carbapenem. Isolates were obtained from urine (71%), lower respiratory tract (7%), blood (7%), wound swabs (8%) or other specimens (7%).
Of the 89 carbapenem-non-susceptible isolates, 32 (36%) were shown to harbour a carbapenemase gene. The proportion of CPE among the carbapenem-non-susceptible isolates submitted from each participating laboratory varied between 0% and 100% (median ¼ 25%, IQR ¼ 0% -63%). Twelve of the 21 laboratories (57%) isolated at least one CPE. Carbapenem-non-susceptible E. coli harboured a carbapenemase gene less frequently than carbapenem-non-susceptible K. pneumoniae (18% versus 49%, P¼0.004). Table 1 shows the proportion of the various carbapenemases; KPC (44%) and OXA-48-like (38%) were the most frequent.
The sources (blood, urine, etc.) of the isolates were similar for CPE and other carbapenem-non-susceptible isolates.
Antibiotic susceptibility
All 89 carbapenem-non-susceptible isolates were intermediate or resistant to ertapenem, but most were still susceptible to imipenem (59%) or meropenem (64%). CPE were generally more often resistant than non-CPE, notably to piperacillin/tazobactam (100% versus 83%, P ¼ 0.02), imipenem (47% versus 2%, P, 0.001), meropenem (63% versus 2%, P, 0.001), amikacin (34% versus 2%, P,0.001) and tobramycin (69% versus 45%, P¼ 0.05). Nine CPE were susceptible to imipenem or meropenem despite nonsusceptibility to ertapenem, of which eight produced OXA-48-like carbapenemases and one a VIM carbapenemase.
Most carbapenem-non-susceptible isolates were susceptible to colistin (97%), along with aminoglycosides (74% susceptible to amikacin, 59% to gentamicin and 41% to tobramycin) and tigecycline (64% susceptible). However, most isolates were nonsusceptible to ceftazidime (88%), aztreonam (86%) and ciprofloxacin (74%). CPE isolates were resistant to most antibiotics, except colistin (94% susceptible), gentamicin (63%), tigecycline (56%) and amikacin (53%).
The meropenem MICs for four carbapenem-non-susceptible isolates were below the EUCAST screening cut-off value for suspected CPE (0.12 mg/L), but these were not confirmed as CPE. The meropenem and ertapenem MICs were above the EUCAST screening cut-off values for all CPE, but the imipenem MIC for one CPE isolate was below the screening cut-off value (MIC¼1 mg/L, screening cut-off value .1 mg/L).
Prevalence and incidence
In these sentinel sites and amongst all clinical isolates, the period prevalence of carbapenem-non-susceptible isolates and CPE was 0.07% (95% CI ¼ 0.05% -0.09%) and 0.02% (95% CI ¼ 0.01% -0.03%), respectively. The prevalence of carbapenem-non-susceptible isolates was much higher for K. pneumoniae than for E. coli (0.75% versus 0.03%, P, 0.001), as was the prevalence of CPE (0.41% versus 0.01%, P,0.001). Trepanier et al.
The incidence of carbapenem-non-susceptible isolates was 0.02 per 1000 patient-days (95% CI¼0.016-0.025) and the incidence of CPE was 0.007 per 1000 patient-days (95% CI¼0.005-0.010) (excluding one laboratory for which patient-days data were unavailable). Figure 1 shows the regional incidence of CPE per 1000 patient-days. North-west England had the highest incidence at 0.033 per 1000 patient-days (95% CI ¼ 0.012-0.072).
Epidemiological characteristics
The epidemiological characteristics of carbapenem-nonsusceptible isolates are shown in Table 2 . Most (70%) were from community-onset infections, although 42% of patients with community-onset CPE had a previous hospital admission in the past 6 months (unknown for 32%). There were no significant differences between E. coli and K. pneumoniae.
Questionnaire
All participating laboratories completed the questionnaire. Two participants did not reply to all questions, and therefore were excluded from the analysis for these questions.
During the year preceding the EuSCAPE study most respondents (79%) had isolated carbapenem-non-susceptible Enterobacteriaceae in their laboratories; the median number of confirmed CPE was 3 isolates per year (range¼0-48, IQR¼1-9). The median numbers of KPC, OXA-48-like, NDM and VIM producers isolated during the year preceding the study were 1 (range ¼ 0 -36, Epidemiology of CPE in the UK JAC IQR¼0-1),1(range¼0-10,IQR¼0-2), 1(range¼0-20, IQR¼0-2) and 0 (range¼0-3, IQR¼0-1), respectively. No IMP producers were identified at any sentinel site in the previous year.
Laboratory methods
The primary susceptibility testing methods used at sentinel sites were antibiotic discs (13/21 laboratories) followed by automated systems (5), both automation and discs (2) , and agar dilution (1). All laboratories used at least one other susceptibility testing method occasionally: MIC gradient tests (16), antibiotic discs (11), automation (4) or other techniques (3) such as molecular methods. The majority defined a carbapenem-non-susceptible Enterobacteriaceae with the BSAC/EUCAST clinical breakpoints (15), followed by EUCAST's recommended screening criteria (5) or CLSI clinical breakpoints (1). None used EUCASTepidemiological cut-off values.
Eighteen respondents reported having a laboratory protocol for screening rectal swabs or faeces for carbapenem-non-susceptible Enterobacteriaceae as recommended by PHE. Chromogenic agars (11) or MacConkey/CLED agars with carbapenem discs (8) were used most often. One laboratory each reported using prior enrichment broth, ESBL chromogenic agar with an ertapenem disc, or an in-house screening agar. Four laboratories used more than one method.
All the laboratories that identified carbapenem-non-susceptible Enterobacteriaceae prior to EuSCAPE sent the isolates to a reference laboratory for confirmation, as advocated by the UK Standards for Microbiology Investigations (SMI)-Laboratory Detection and Reporting of Bacteria with Carbapenem-Hydrolysing b-Lactamases (Carbapenemases). 17 All except one also performed additional tests locally: phenotypic tests (13) including modified Hodge test (9), inhibitor-based tests (8), MALDI-TOF MS (1) and Carba-NP (1), MIC testing (12) or molecular tests (5). All respondents were aware of the UK SMI.
IPC measures
Most participants (18) reported that on-admission screening for carbapenem-non-susceptible Enterobacteriaceae was undertaken locally for some patients. The screening indications are presented in Table 3 . The specimens used for screening were rectal swab (18) and/or stool (10), but also clinical sites: wound swab (10), lines and devices (8) , urine (3) and throat swab (1). Despite recommendations, only 3/19 respondents with an outpatient haemodialysis unit screened those patients for carbapenem-non-susceptible Enterobacteriaceae. (20) 59 (25) 60 (23) Epidemiological context hospital acquisition 11 (34) 14 (25) 25 (28) As recommended by PHE. 19 Trepanier et al.
The IPC measures applied if a patient was infected or colonized with carbapenem-non-susceptible Enterobacteriaceae are presented in Table 4 . Most centres (16) had a management plan as recommended by PHE (one laboratory did not respond to this question); plans were implemented between 2011 and 2014, with the majority in 2014 (9) . As recommended, training on the management plan was generally provided for nurses (13) , medical staff (11) and other staff (11) . All laboratories had a system to alert IPC staff in a timely manner (i.e. within 24 h) whenever a carbapenem-non-susceptible Enterobacteriaceae isolate was identified. Finally, all facilities audited hand hygiene and had an antibiotic stewardship programme, following UK guidelines. 18 All participants were aware of the existence of the Acute Trust Toolkit for the Early Detection, Management and Control of Carbapenemase-Producing Enterobacteriaceae published by PHE; 19 19 had started plans for its implementation.
Discussion
The EuSCAPE-UK study provides, to our knowledge, the first estimate of the prevalence and incidence of clinically significant, carbapenem-non-susceptible Enterobacteriaceae in the UK via a network of sentinel laboratories. The main finding of our study is that the prevalence and incidence of carbapenem-non-susceptible Enterobacteriaceae and CPE in the UK, although low, is not negligible. Most (17) of the 21 participating laboratories (which included two 'pooled' Scottish Microbiology Reference Laboratories) isolated carbapenem-non-susceptible isolates during the study period and 12 isolated at least one CPE isolate. All but two UK regions submitted at least one carbapenem-non-susceptible isolate for reference investigation; one did not isolate any clinically significant isolates in the survey period and another did not submit isolates within the collection period. The EuSCAPE study only focused on K. pneumoniae and E. coli; therefore, possibly leading to an underestimate of the CPE prevalence. However, these two organisms account for .77% of CPE referred to AMRHAI in 2013 -14 (K. L. Hopkins, AMRHAI, unpublished data) and as only 10 isolates were collected per laboratory it is unlikely that other Enterobacteriaceae would have significantly contributed to the collection. Among confirmed CPE we found various carbapenemases, with a predominance of KPC in K. pneumoniae (54%) and OXA-48-like in E. coli (56%). This contrasts with some previous European studies showing usually a far higher prevalence of one type of carbapenemase in K. pneumoniae (e.g. 95% of KPC in Italy, 20 76% of OXA-48 in France   21 ). Previous studies showed clonal diversity of CPE in the UK. 22, 23 Future work will involve typing by WGS of isolates from all countries participating in the EuSCAPE study to assess clonality.
It should be noted that CPE were sought only among carbapenem-non-susceptible E. coli and K. pneumoniae, based on the EuSCAPE protocol, though it is known that not all CPE exhibit resistance to carbapenems according to clinical breakpoints. 24 Nonetheless, detecting CPE is of crucial importance for IPC. Only 24% of respondents used the EUCAST-recommended screening criteria for suspected CPE (defined by MIC thresholds lower than EUCAST's clinical breakpoints), so some CPE may have been undetected. The fact that 25% of CPE were susceptible to meropenem and 16% to imipenem highlights the risk of missing CPE if only clinical breakpoints are used.
We found a similar prevalence of carbapenem-non-susceptible E. coli and K. pneumoniae (among all clinical isolates of those species) to that reported in the EARS-Net 2013 report, considering the 95% CIs. 25 However, the EARS-Net reporting system includes only data on invasive isolates, whilst we collected data on all types of clinical isolates.
Interestingly, 59% of our cases were not healthcare acquired using a widely accepted definition of nosocomial (i.e. onset was in outpatients or within 48 h of hospitalization), whilst many published descriptions of CPE are healthcare associated. 9 Long-term carriage of CPE (.6 months) is described, 26 but genuine community transmission has rarely been reported. 4 More likely, apparent community-onset CPE infections may result from previous acquisition in healthcare settings. Indeed, almost half (47%) of patients categorized as having a community-onset infection had been hospitalized in the previous 6 months, and the information was unavailable for a further 31% of them.
All regional incidence measures should also be interpreted with caution since regional numbers of cases are very low. Moreover, these are crude estimates without standardization. Nevertheless, the study gives an overall picture of the regional burden of CPE, with north-west England the most affected region when estimated based on patient-days. Ongoing transmission has been problematic in the latter region in recent years. 4 Information on travel history was available for too few isolates to draw conclusions. However, at least 7/32 (22%) patients infected with a CPE had not travelled abroad within the previous 6 months, with travel history unknown for all bar one of the remaining patients. This suggests transmission within the UK and a potentially higher prevalence of CPE, considering possible Epidemiology of CPE in the UK JAC asymptomatic colonization in the population. In previous publications, CPE was often associated with travel to endemic regions, apart from nosocomial transmission following importation. 27 An ongoing change in transmission patterns is possible and should be evaluated in further studies.
Laboratory protocols for CPE screening differed greatly between the participants, with local habits, preferences and budgets as possible explanations, and the screening indications for CPE generally conformed with UK guidelines. 19 However, some of the IPC measures for CPE carriers were suboptimal, especially in centres without a management plan. Most concerning were the relatively low proportion of centres with a system to 'flag' positive results on patients' records (70%) and the fact that less than a third (30%) of respondents reported that they would alert neighbouring trusts when transferring a known CPE-affected patient. Nevertheless, all respondents had started plans for the application of the Acute Trust Toolkit for the Early Detection, Management and Control of Carbapenemase-Producing Enterobacteriaceae, 19 so IPC measures will hopefully improve in the future.
Surveillance is a well-established cornerstone of IPC. Indeed, 17 European countries have a mandatory reporting system for CPE. 28 A few initiatives have proved to be successful in other regions of the world 29, 30 and better surveillance is widely advocated. In April 2015, enhanced surveillance of CPE in the UK was implemented via a web-based electronic reporting system (ERS), which collects information on patient demographics, submitting laboratory (including specimen details), healthcare setting and risk factors. 31 Regular analysis of data captured by the ERS will allow identification of patient groups that may be more affected by CPE, monitor changes in the epidemiology of these bacteria and evaluate IPC interventions.
A final important issue is the lack of uniformity in the design of similar studies and the plethora of potential indicators. This variability considerably complicates comparisons with other regions of the world. For example, some studies report all carbapenem-non-susceptible Enterobacteriaceae, others report all carbapenem-non-susceptible Gram-negative bacilli, while others focus on carbapenemase-producing isolates (again either Enterobacteriaceae or a wider group of Gram-negatives). Moreover, some include colonization isolates while others include only isolates responsible for clinical infections or do not specify if colonization is included. To our knowledge, there is no consensus guideline advocating an agreed reporting method. Such a tool would facilitate benchmarking and further studies on appropriate control methods.
In conclusion, the prevalence and incidence of clinically significant carbapenem-non-susceptible Enterobacteriaceae and CPE in the UK was noteworthy, although small. North-west England was the region most affected by CPE based on patient-days. Only one UK region (east of England) failed to detect at least one carbapenem-non-susceptible isolate during the 6 month survey. We conclude that continued vigilance and improved monitoring of CPE are required throughout the UK to monitor the impact of intervention measures.
